Teladoc Health, Inc. (NYSE:TDOC) Insider Sells $39,842.88 in Stock

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) insider Adam C. Vandervoort sold 5,808 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $6.86, for a total transaction of $39,842.88. Following the completion of the sale, the insider now owns 69,773 shares of the company's stock, valued at $478,642.78. This trade represents a 7.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Teladoc Health Trading Down 2.7%

NYSE:TDOC traded down $0.20 on Thursday, hitting $6.93. 5,451,781 shares of the stock were exchanged, compared to its average volume of 6,260,841. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -1.20 and a beta of 1.82. Teladoc Health, Inc. has a 52 week low of $6.35 and a 52 week high of $15.21. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. The company's 50-day moving average price is $7.18 and its 200 day moving average price is $9.16.

Analysts Set New Price Targets

A number of brokerages have issued reports on TDOC. Stifel Nicolaus cut their target price on shares of Teladoc Health from $9.00 to $8.00 and set a "hold" rating for the company in a research report on Thursday, May 1st. Truist Financial lowered their target price on shares of Teladoc Health from $10.00 to $9.00 and set a "hold" rating for the company in a report on Tuesday, May 27th. Wells Fargo & Company reduced their price target on shares of Teladoc Health from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Canaccord Genuity Group reduced their price target on shares of Teladoc Health from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Finally, Bank of America reduced their target price on shares of Teladoc Health from $8.00 to $7.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 28th. Twelve analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $9.60.

Institutional Trading of Teladoc Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Golden State Wealth Management LLC increased its stake in Teladoc Health by 102.6% during the 1st quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider's stock worth $27,000 after purchasing an additional 1,690 shares in the last quarter. National Bank of Canada FI raised its stake in Teladoc Health by 79.4% in the 1st quarter. National Bank of Canada FI now owns 3,571 shares of the health services provider's stock valued at $28,000 after acquiring an additional 1,581 shares during the period. Whipplewood Advisors LLC bought a new stake in Teladoc Health in the 4th quarter valued at $29,000. Lindbrook Capital LLC increased its position in Teladoc Health by 78.9% during the 4th quarter. Lindbrook Capital LLC now owns 3,654 shares of the health services provider's stock worth $33,000 after buying an additional 1,612 shares during the period. Finally, SVB Wealth LLC bought a new position in Teladoc Health during the 1st quarter worth $37,000. 76.82% of the stock is owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.